Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Cash from Operations (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Cash from Operations data on record, last reported at 12059722.0 in Q1 2026.

  • On a quarterly basis, Cash from Operations fell 193.89% to 12059722.0 in Q1 2026 year-over-year; TTM through Mar 2026 was 35742656.0, a 84.39% decrease, with the full-year FY2025 number at 27786464.0, down 45.11% from a year prior.
  • Cash from Operations reached 12059722.0 in Q1 2026 per IKT's latest filing, down from 7515973.0 in the prior quarter.
  • Over the last five years, Cash from Operations for IKT hit a ceiling of 3442431.0 in Q4 2023 and a floor of 12059722.0 in Q1 2026.
  • A 5-year average of 5554729.35 and a median of 4881100.0 in 2024 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: soared 35.25% in 2024, then tumbled 193.89% in 2026.
  • Tracing IKT's Cash from Operations over 5 years: stood at 3556374.0 in 2022, then rose by 3.2% to 3442431.0 in 2023, then plummeted by 55.28% to 5345575.0 in 2024, then plummeted by 40.6% to 7515973.0 in 2025, then plummeted by 60.45% to 12059722.0 in 2026.
  • Business Quant data shows Cash from Operations for IKT at 12059722.0 in Q1 2026, 7515973.0 in Q4 2025, and 10592730.0 in Q3 2025.